
Solifenacin (5mg) + Mirabegron (25mg)
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirabig-S 25 Tablet ER is a once-daily, extended-release formulation that combines the muscarinic receptor antagonist, mirabegron (25mg), and the beta-3 adrenergic receptor agonist, solifenacin (5mg). This innovative medication is designed to treat symptoms of overactive bladder (OAB), including urinary frequency, urgency, and incontinence, as well as storage symptoms such as nocturia and hesitancy. Mirabig-S 25 Tablet ER works by relaxing the detrusor muscle and increasing bladder capacity, thereby reducing the frequency of urinary episodes. The medication's unique extended-release mechanism ensures consistent therapeutic levels throughout the day, providing prolonged symptom relief. This dual-action formulation allows for a balanced approach to managing OAB symptoms, minimizing the risk of anticholinergic side effects and preserving bladder function. As a convenient, once-daily treatment option, Mirabig-S 25 Tablet ER offers patients a reliable and effective solution for managing the daily challenges of overactive bladder.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirabig-S 25 Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirabig-S 25 Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirabig-S 25 Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirabig-S 25 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirabig-S 25 Tablet ER in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirabig-S 25 Tablet ER

Mirabegron (25mg) + Solifenacin (5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirabig-S 25 Tablet ER is a once-daily, extended-release formulation that combines the muscarinic receptor antagonist, mirabegron (25mg), and the beta-3 adrenergic receptor agonist, solifenacin (5mg). This innovative medication is designed to treat symptoms of overactive bladder (OAB), including urinary frequency, urgency, and incontinence, as well as storage symptoms such as nocturia and hesitancy. Mirabig-S 25 Tablet ER works by relaxing the detrusor muscle and increasing bladder capacity, thereby reducing the frequency of urinary episodes. The medication's unique extended-release mechanism ensures consistent therapeutic levels throughout the day, providing prolonged symptom relief. This dual-action formulation allows for a balanced approach to managing OAB symptoms, minimizing the risk of anticholinergic side effects and preserving bladder function. As a convenient, once-daily treatment option, Mirabig-S 25 Tablet ER offers patients a reliable and effective solution for managing the daily challenges of overactive bladder.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirabig-S 25 Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirabig-S 25 Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirabig-S 25 Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirabig-S 25 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirabig-S 25 Tablet ER in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirabig-S 25 Tablet ER















